NEW YORK, March 10, 2016 /PRNewswire/ -- Spheryx, Inc. will demonstrate the capabilities of Total Holographic Characterization™ at the 251st American Chemical Society National Meeting and Exposition, from March 13-15, in booth 1435 where Chief Technology Office, Dr. Fook Cheong will be performing particle characterization analyses. Dr. David Ruffner, Director of Analytical Services, will make an oral presentation titled "Holographic Characterization of Individual Colloids in Complex Mixtures" on March 16 at 9:30 am in room 24B, and a poster presentations titled "Holographic Imaging of Protein Aggregates, Slurry Agglomerates, and Wastewater Contaminants" on March 13 at 8:00 pm in Hall E of the San Diego Convention Center. Dr. Laura Philips, Spheryx CEO stated, "The ACS meeting provides a great forum to introduce our technology to a wide array of industries where Total Holographic Characterization™ can become a useful tool to solve particle characterization problems from R&D to quality assurance and manufacturing process control."
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization™ of colloidal materials. Spheryx's breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials' characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information please visit the company's website at http://www.spheryx.solutions/
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially. These risks and uncertainties include, among others: the results, timing and costs of our studies; our ability to obtain future funding on acceptable terms; the possible impairment of, or inability to obtain intellectual property rights; and innovation by our competitors.
Laura Philips, CEO
SOURCE Spheryx, Inc.